Markets

Humana Downgraded to a “Sell” by Goldman Sachs (HUM)

Goldman Sachs has downgraded healthcare company, Humana Inc.( HUM ) to a "Sell" Wednesday.

The firm has downgraded HUM to a "Sell", and has dropped its price target for the company by 19% from $77 to $62. This price target suggests a 16% decrease from the stock's current price of $73.98.

An analyst from the firm noted, "with health reform now more likely to move ahead following the election outcome, we see greater downside risk to Medicare Advantage, which we estimate comprises over 70% of the HUM's earnings."

Humana shares were down $2.18, or -2.86% during premarket trading Wednesday. The stock is down -13.07% YTD.

The Bottom Line

Shares of Humana ( HUM ) have a 1.37% dividend yield, based on last night's closing stock price of $76.16. The stock has technical support in the $70 price area. If the shares can firm up, we see overhead resistance around the $80 price level.

Humana Inc.( HUM ) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.2 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Created by Dividend.com


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

HUM

Other Topics

Stocks

Latest Markets Videos